摘要
目的观察右丙亚胺联合参芪扶正注射液减轻乳腺癌FAC方案所致心脏毒性的效果。方法本研究入组60例乳腺癌患者随机分为2组。实验组32例，采用右丙亚胺和参芪扶正注射液治疗；对照组28例，单用右丙亚胺治疗。所有患者化疗6个周期，分别监测化疗前后患者的生活质量、不良反应、心功能、cTnT浓度及LVEF的变化。结果实验组患者QOL改善率明显高于对照组，差异有统计学意义（P〈0．05）。实验组患者Ⅰ～Ⅳ度骨髓抑制发生率明显低于对照组，差异有统计学意义（P〈0．05）。2组患者治疗前后的cTnT浓度比较差异具有统计学意义（P〈0．05）。2组患者治疗前后的LVEF比较差异无统计学意义（P〉0．05）。结论右丙亚胺联合参芪扶正注射液可有效减轻乳腺癌患者接受FAC方案所致早期心脏毒性，降低骨髓抑制的发生率，提高生活质量。
Objective To observe the effect of Dexrazoxane combined with Shenqi Fuzheng Injection on reducing multiple cardiotoxicity in breast malignancy patients with FAC chemotherapy regimen. Methods Sixty patients with breast cancer were randomly divided into two groups. The experimental group （30 cases） was treated with Dexrazoxane and Shenqi Fuzheng Injection. The control group （30 cases） was treated only with Dexrazoxane. Both groups received six complete cycles of chemotherapy. The quality of life, adverse reactions, cardiac function, cardiac troponin T（cTnT） and left ventricular ejec- tion fraction（LVEF） values of both groups were observed before and after chemotherapy. Results QOL improvement rate was significantly higher in patients in the experimental group than that in control group, the difference was statistically signif- icant （ P 〈 0.05）. I-IV degree of bone marrow suppression in patients in the experimental group was significantly lower than that of the control group, the difference was statistically significant （ P 〈 0.05）. The level of cTnT in patients of both groups were significant different （ P 〈 0.05） before and after treatment. There was no difference between two groups on LVEF nei- ther before nor after treatment （ P 〉 0.05）. Conclusion Dexrazoxane combined with Shenqi Fuzheng Injection were effec- tive in preventing chemotherapy-induced cardiotoxicity in breast cancer patients treated with FAC. They can reduce the inci- dence of bone marrow suppression and improve the quality of life of patients.
出处
《吉林中医药》
2014年第3期256-259,共4页
Jilin Journal of Chinese Medicine
